Azurity Pharmaceuticals, a portfolio company of QHP Capital, announced that it acquired select assets from Sebela Pharmaceuticals. The transaction includes two leading bowel preparation therapies for colonoscopies.
Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in gastroenterology and a focus on innovation in women’s health.
Founded in 1998, Azurity Pharmaceuticals focuses on the needs of special patient populations, such as children and the elderly, for whom customized doses and user-friendly formulations tailored to their needs do not exist. It is based in Woburn, Massachusetts.
By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States.
Barclays served as financial advisor and Eversheds Sutherland served as legal advisor to Azurity. Jefferies served as financial advisor and Mayer Brown served as legal advisor to Sebela.
According to data in the LevinPro HC database, this transaction represents the 44th Pharmaceuticals acquisition of the year, accounting for 2% of the healthcare transactions. There were 66 Pharmaceuticals deals in 2024. This also represents Azurity’s second acquisition of 2025; in March, the company acquired Covis Pharma, a specialty pharmaceutical company, from Cerberus Capital Management.
